Immunitybio Shareholder Alert: Claimsfiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Immunitybio, Inc. - IBRX
Get Help
ImmunityBio investors should visit us at or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations“are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.”
On this news, the price of ImmunityBio's shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.
The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit .
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment